Format

Send to

Choose Destination
Urology. 1997 Apr;49(4):632-4.

Antiandrogen withdrawal syndrome with nilutamide.

Author information

1
Division of Medical Oncology, Ottawa Regional Cancer Centre, Ontario, Canada.

Abstract

Antiandrogens are combined with medical or surgical castration to achieve total androgen blockade in metastatic prostate cancer. Discontinuation of antiandrogens at disease progression has been associated with prostate-specific antigen (PSA) decrease, symptom improvement, and occasionally objective tumor regression. Two cases of metastatic prostate cancer demonstrating decrease in PSA of 92% and 56% on discontinuation of nilutamide therapy are reported. Improvement in urinary symptoms, bone pain and, in one, disappearance of para-aortic lymphadenopathy paralleled the PSA decrease. The duration of the withdrawal response of 6 months was comparable to those reported with discontinuation of flutamide.

PMID:
9111642
DOI:
10.1016/s0090-4295(96)00558-4
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center